ES2606762T3 - Anticuerpos contra CD38 para el tratamiento del mieloma múltiple - Google Patents

Anticuerpos contra CD38 para el tratamiento del mieloma múltiple Download PDF

Info

Publication number
ES2606762T3
ES2606762T3 ES06722861.9T ES06722861T ES2606762T3 ES 2606762 T3 ES2606762 T3 ES 2606762T3 ES 06722861 T ES06722861 T ES 06722861T ES 2606762 T3 ES2606762 T3 ES 2606762T3
Authority
ES
Spain
Prior art keywords
antibody
seq
cd38bp
human
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06722861.9T
Other languages
English (en)
Spanish (es)
Inventor
Michel De Weers
Yvo Graus
Judith Oprins
Paul Parren
Jan Van De Winkel
Martine Van Vugt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Priority claimed from PCT/DK2006/000166 external-priority patent/WO2006099875A1/en
Application granted granted Critical
Publication of ES2606762T3 publication Critical patent/ES2606762T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES06722861.9T 2005-03-23 2006-03-23 Anticuerpos contra CD38 para el tratamiento del mieloma múltiple Active ES2606762T3 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA200500429 2005-03-23
DK200500429 2005-03-23
US66757905P 2005-04-01 2005-04-01
US667579P 2005-04-01
US69616305P 2005-07-01 2005-07-01
US696163P 2005-07-01
US72856105P 2005-10-20 2005-10-20
US728561P 2005-10-20
PCT/DK2006/000166 WO2006099875A1 (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
ES2606762T3 true ES2606762T3 (es) 2017-03-27

Family

ID=50644285

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06722861.9T Active ES2606762T3 (es) 2005-03-23 2006-03-23 Anticuerpos contra CD38 para el tratamiento del mieloma múltiple
ES12178778.2T Active ES2644982T3 (es) 2005-03-23 2006-03-23 Anticuerpos contra CD38 para el tratamiento del mieloma múltiple

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12178778.2T Active ES2644982T3 (es) 2005-03-23 2006-03-23 Anticuerpos contra CD38 para el tratamiento del mieloma múltiple

Country Status (12)

Country Link
KR (1) KR20140033240A (it)
BE (1) BE2017C062I2 (it)
DK (1) DK1866338T3 (it)
ES (2) ES2606762T3 (it)
HU (2) HUE034962T2 (it)
LT (2) LT1866338T (it)
NZ (2) NZ600059A (it)
PL (1) PL1866338T3 (it)
PT (2) PT1866338T (it)
RS (1) RS55442B1 (it)
SG (1) SG10201610317VA (it)
UA (2) UA98756C2 (it)

Also Published As

Publication number Publication date
BE2017C062I2 (it) 2025-12-03
LT1866338T (lt) 2017-01-25
NZ600059A (en) 2016-01-29
SG10201610317VA (en) 2017-02-27
ES2644982T3 (es) 2017-12-01
UA98756C2 (ru) 2012-06-25
HUE030783T2 (en) 2017-06-28
HUE034962T2 (en) 2018-03-28
KR20140033240A (ko) 2014-03-17
LT2567976T (lt) 2017-12-11
PL1866338T3 (pl) 2017-04-28
DK1866338T3 (da) 2017-01-02
NZ625944A (en) 2016-01-29
RS55442B1 (sr) 2017-04-28
UA116520C2 (uk) 2018-04-10
PT2567976T (pt) 2017-10-19
PT1866338T (pt) 2016-12-14

Similar Documents

Publication Publication Date Title
US20240228662A9 (en) Antibodies against cd38 for treatment of multiple myeloma
US20090076249A1 (en) Antibodies against CD38 for treatment of multiple myeloma
ES2606762T3 (es) Anticuerpos contra CD38 para el tratamiento del mieloma múltiple
HK40048777A (en) Antibodies against cd38 for treatment of multiple myeloma
HK1236545A1 (en) Antibodies against cd38 for treatment of multiple myeloma
HK1179979B (en) Antibodies against cd38 for treatment of multiple myeloma
HK1179979A (en) Antibodies against cd38 for treatment of multiple myeloma
HK1183047B (en) Antibodies against cd38 for treatment of multiple myeloma
HK1107826B (en) Antibodies against cd38 for treatment of multiple myeloma
HK1183047A (en) Antibodies against cd38 for treatment of multiple myeloma